Sorrento Announces Positive Preliminary Results of Phase 1b Study of COVI-MSC™ for Treatment of ICU COVID-19 Patients

NEXT STORY
Predictive Oncology Announces Closing of $4.1 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
PREV STORY
Apellis Announces Closing of Previously Announced Exchanges of Approximately $126.1 Million in Principal Amount of Its 3.500% Convertible Senior Notes Due 2026 for Common Stock
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

ADMA Biologics Added to the Russell 3000 and Russell 2000 Indexes

RAMSEY, N.J. and BOCA RATON, Fla., June 25, 2018 (GLOBE NEWSWIRE) -- ADMA Biologics, ...

author_avatar
NASDAQ Market News

Stemline Therapeutics Prices $51.8 Million Public Offering of Common Stock

NEW YORK, Jan. 24, 2018 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage ...

author_avatar
NASDAQ Market News

XBiotech Highlights Third Quarter Developments for 2018

Company Provides Updated Overview including on its Clinical and Discovery Pipeline as well as ...

author_avatar
NASDAQ Market News